Medical News

---

• Von Willebrand Factor critical for DVT formation
• AVERROES: Apixaban bleeding profile no worse than with aspirin
• Systemic therapy could reduce CV risk in psoriasis patients
• Cell cycle progression is ‘robust’ prognostic marker for prostate cancer
• Cell cycle progression is ‘robust’ prognostic marker for prostate cancer
• Inflammatory markers independently linked to CHD risk
• Dyslipidemic genetic predisposition does not prevent low-fat diet improving lipid profile
• Low-carb diets high in red or processed meat raise risk for Type 2 diabetes
• Diabetes, BP predict cardiovascular events, but not synergistically
• Wireless implant cuts HF hospitalization rates
• AVERROES: Apixaban bleeding profile no worse than with aspirin
• Benazepril-amlodipine offers no antihypertensive benefit over benazepril-hydrochlorothiazide

Von Willebrand Factor critical for DVT formation Posted: 10 Feb 2011 04:00 PM PST Von Willebrand Factor-mediated platelet adhesion is essential for flow reduction-induced deep vein thrombosis in mouse models, study findings indicate.

AVERROES: Apixaban bleeding profile no worse than with aspirin Posted: 10 Feb 2011 04:00 PM PST The risk for major or intracranial bleeding among atrial fibrillation patients taking the factor Xa inhibitor apixaban is much the same as among those taking aspirin, show the full results from the AVERROES trial.

Systemic therapy could reduce CV risk in psoriasis patients Posted: 10 Feb 2011 04:00 PM PST Patients with severe plaque-type psoriasis who respond well to continuous systemic therapy experience a simultaneous reduction in levels of biomarkers that indicate cardiovascular risk, show study findings.

Cell cycle progression is ‘robust’ prognostic marker for prostate cancer Posted: 10 Feb 2011 04:00 PM PST Levels of expression of cell cycle progression genes – those that encourage cell growth – could have an essential role in determining the appropriate treatment for patients with prostate cancer, say researchers.

Cell cycle progression is ‘robust’ prognostic marker for prostate cancer Posted: 10 Feb 2011 04:00 PM PST Levels of expression of cell cycle progression genes – those that encourage cell growth – could have an essential role in determining the appropriate treatment for patients with prostate cancer, say researchers.

Inflammatory markers independently linked to CHD risk Posted: 10 Feb 2011 04:00 PM PST Researchers report that abdominal obesity and physical inactivity are strong and independent predictors of coronary heart disease risk, and that several markers of inflammation are linearly associated with these risk factors in both men and women.

Dyslipidemic genetic predisposition does not prevent low-fat diet improving lipid profile Posted: 10 Feb 2011 04:00 PM PST Research suggests that a common genetic predisposition to dyslipidemia affects lipid profiles of patients on a habitual diet, but does not affect changes in lipid profiles due to reduced dietary intake of saturated fatty acids.

Low-carb diets high in red or processed meat raise risk for Type 2 diabetes Posted: 10 Feb 2011 04:00 PM PST Consumption of low-carbohydrate diets high in red or processed meat are associated with an increased risk for Type 2 diabetes in men, report US researchers.

Diabetes, BP predict cardiovascular events, but not synergistically Posted: 10 Feb 2011 04:00 PM PST The presence of diabetes and elevated 24-hour ambulatory blood pressure are both independently associated with increased risk for cardiovascular disease-related events, but there is no evidence for a synergistic interaction between the two risk factors, suggest study results.

Wireless implant cuts HF hospitalization rates Posted: 10 Feb 2011 04:00 PM PST Using a wireless implantable hemodynamic monitoring system in patients with New York Heart Association class III heart failure may substantially reduce their risk for hospitalization, according to results from the CHAMPION study.

AVERROES: Apixaban bleeding profile no worse than with aspirin Posted: 10 Feb 2011 04:00 PM PST The risk for major or intracranial bleeding among atrial fibrillation patients taking the factor Xa inhibitor apixaban is much the same as among those taking aspirin, show the full results from the AVERROES trial.

Benazepril-amlodipine offers no antihypertensive benefit over benazepril-hydrochlorothiazide Posted: 10 Feb 2011 04:00 PM PST Findings from a subanalysis of the ACCOMPLISH trial suggest that combination therapy using benazepril plus amlodipine results in similar 24-hour blood pressure control as with combined benazepril and hydrochlorothiazide.

You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610